Clinical Trial Update: Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of Tulisokibart (MK-7240-012) for hidradenitis suppurativa is currently active but not recruiting, sponsored by Merck Sharp & Dohme LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• Tulisokibart

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hidradenitis Suppurativa | Phase 2 | Status: ACTIVE_NOT_RECRUITING